Roche's Itovebi combination for breast cancer gets EU nod

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) (OTCPK:RHHVF) said that the European Commission has approved its oral cancer drug, Itovebi (inavolisib), to be used alongside palbociclib and fulvestrant for breast cancer treatment. 

This treatment is intended for adult patients who have a specific genetic mutation and have breast cancer that is hormone receptor-positive and HER2-negative.

This includes cases that are locally advanced or have spread to other parts of the body, especially if the cancer has returned within a year after finishing hormone therapy.

The approval is based on data from the INAVO120 study, which demonstrated that the combination treatment with Itovebi significantly improved the time patients lived without their cancer worsening, more than doubling the duration compared to using palbociclib and fulvestrant alone.